Godrej Properties Ltd reported a 22% year-on-year rise in pre-sales to Rs 86.5 billion in the first quarter of FY27, an 8% beat on brokerage estimates, driven by strong launches across Bengaluru, t
News in Focus


Motilal Oswal Financial Services has retained its BUY rating on DLF Limited, setting a target price of Rs755, implying a 17% upside from the current market price of Rs643.

Motilal Oswal has reiterated a BUY rating on Blue Dart Express with a target price of Rs 6,100, implying 15% upside from the current market price of Rs 5,284.

Maharashtra has become the first Indian state to formally outlaw analogue paneer, a non-dairy imitation product linked to health complaints, in a sweeping one-year ban announced by Food and Drugs A

Artificial intelligence is systematically reshaping the labor market, but not uniformly.

Motilal Oswal Financial Services has reiterated a Buy rating on Cummins India, trimming its target price slightly to Rs 6,500 from Rs 6,600, still implying 20% upside from the current market price
Main Regional Stories

Motilal Oswal Financial Services has reiterated a Buy rating on Godrej Agrovet, holding its target price at Rs 675, implying 24% upside from the current market price of Rs 545.

Motilal Oswal reiterated a "Buy" rating for Biocon with a price target of Rs520. The target has been revised but positive view on the stock remains intact. Overall market sentiment is positive for pharmaceutical sector.

Motilal Oswal Financial Services has reiterated a Buy rating on Life Insurance Corporation, raising its target price to Rs 480, implying 24% upside from the current market price of Rs 388.

Motilal Oswal Financial Services has reiterated a Buy rating on Devyani International, holding its target price at Rs 160, implying 35% upside from the current market price of Rs 118.
Sharekhan Research maintained purchase rating on Sun Pharmaceutical Industries with target price of Rs 1287. At current market price Rs 965, stock valued at 21.6x FY2008E and 18.1xFY2009E fully diluted earnings.
said that it may increase term depository rates b
Ranbaxy Laboratories leads the gainers path on the Sensex. In morning trades, the share is quoting at Rs 364.40, which is up Rs 23.35, or 6.85%.
Emkay Research report on GTL:
is defending the contact he made with an AIB official to inquire about transactions under investigation by the Mahon Tribunal. 








